Erbitux (cetuximab)
FDA approves Erbitux (cetuximab) to treat patients with advanced
colorectal cancer that has spread to other parts of the body.
Erbitux is the first monoclonal antibody approved to treat this type
of cancer and is indicated as a combination treatment to be given
intravenously with irinotecan, another drug approved to fight
colorectal cancer, or alone if patients cannot tolerate irinotecan.
Back
to Top
Back to Drug Info
Date created: February 12, 2004; updated April 8, 2004 |